Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk

Annals of Surgical Oncology 2024 February 19 [Link] Varun V Bansal, Owen Mitchell, Celyn Bregio, Hunter D D Witmer, Ankit Dhiman, Frederick A Godley 4th, Cecilia Ong, Yaniv Berger, Biren Reddy, Jane E Churpek, Michael W Drazer, Oliver S Eng, Hedy L Kindler, Kiran K Turaga Abstract Introduction: Venous thromboembolism (VTE) is a common complication…

Read More

Is extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?

Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…

Read More

Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review

Pathology Oncology Research 2024 January 8 [Link] Minying Deng, Xinyi Zhang, Chen Xu, Rongkui Luo, Lingli Chen, Yuhong Zhou, Yingyong Hou Abstract Background: Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse MM: epithelioid, sarcomatoid, desmoplastic,…

Read More

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort

ERJ Open Research 2023 December 27 [Link] Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby Abstract Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma…

Read More

Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…

Read More

Analysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma

Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…

Read More

Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma

International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as…

Read More

Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC

Annals of Surgical Oncology 2023 January [Link] Ambarish Chatterjee, Shigeki Kusamura, Dario Baratti, Marcello Guaglio, Luigi Battaglia, Marcello Deraco Abstract Background: The available data on the role of perioperative systemic chemotherapy (SC) for diffuse malignant peritoneal mesothelioma (DMPM) patients undergoing (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is heterogeneous and unstandardized. This study aimed to evaluate…

Read More

The role of single nucleotide polymorphisms related to iron homeostasis in mesothelioma susceptibility after asbestos exposure: a genetic study on autoptic samples

Frontiers in Public Health 2023 October 24 [Link] Pierangela Grignani, Silvia Damiana Visonà, Maria Vittoria Fronda, Paola Borrelli, Maria Cristina Monti, Barbara Bertoglio, Adelaide Conti, Paolo Fattorini, Carlo Previderè Abstract Asbestos-related diseases still represent a major public health problem all over the world. Among them, malignant mesothelioma (MM) is a poor-prognosis cancer, arising from the…

Read More

Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology

European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…

Read More